Skip to main content
SpringerLink
Log in

Health outcome and quality-of-life measurements in amyotrophic lateral sclerosis

  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Quality of life has been used as a primary outcome measure in the treatment of cancer and cardiovascular disease, and as a secondary disease, and as a secondary outcome measure in therapy of Parkinson’s disease. However, it has been relatively neglected in studies of amyotrophic lateral sclerosis (ALS). Although there is need for the development of an ALS-specific quality-of-life measure, it will be necessary, nonetheless, to continue to use generic measures in order to ensure comparability of measurement between disease states. An argument is put forward for the use of quality-of-life measures as a primary end-point in future clinical trials in ALS. A distinction is drawn between the demonstration of biological efficacy and clinically useful benefit. The most likely instruments to prove useful are briefly discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Testa MA, Simonson DC (1996) Assesment of quality-of-life outcomes. N Engl J Med 334: 835–840

    Article  PubMed  CAS  Google Scholar 

  2. Leigh PN, Swash M (1995) Motor’ neuron disease: biology and management. Springer, London Berlin Heidelberg

    Google Scholar 

  3. Spilker B (1990) Quality of life assessments in clinical trials. Raven, New York

    Google Scholar 

  4. McDowell I, Newell C (1996) Measuring health; a guide to rating scales and questionnaires, 2nd edn. Oxford University Press, Oxford

    Google Scholar 

  5. Brooks BR (1966) Clinical epidemiology of amyotrophic lateral sclerosis. Neurol Clin 14: 399–420

    Article  Google Scholar 

  6. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, for the Amyotrophic Lateral Sclerosis Study Group II (1996) Dose ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347: 1425–1431

    PubMed  CAS  Google Scholar 

  7. Wokke J (1996) Riluzole. Lancet 348: 795–799

    Article  PubMed  CAS  Google Scholar 

  8. The IFNβ Multiple Sclerosis Study Group (1993) Interferon b 1β is effective in relapsing-remitting multiple sclerosis. 1. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655–661

    Google Scholar 

  9. Rudick R, Antel J, Confraveux C, et al (1996) Clinical outcomes assessment in multiple sclerosis. Ann Neurol 40: 469–479

    Article  PubMed  CAS  Google Scholar 

  10. Calman KE (1984) Quality of life in concepts; a hypothesis. J Med Ethics 10: 124–127

    Article  PubMed  CAS  Google Scholar 

  11. Hobart JC, Lamping DL, Thompson AJ (1996) Evaluating neurological outcome measures: the bare essentials. J Neurol Neurosurg Psychiatry 60: 127–130

    Article  PubMed  CAS  Google Scholar 

  12. Ware JE Jr, Kosinski M, Keller SD (1994) SF-36 physical and mental health summary scores: a user’s manual. The Health Institute, New England Medical Center, Boston, Mass

    Google Scholar 

  13. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995) The development and validation of a short measure of functioning and wellbeing for individuals with Parkinson’s disease. Qual Life Res 4: 241–248

    Article  PubMed  CAS  Google Scholar 

  14. Jenkinson C, Peto V, Fitzpatrick R, Greenhall R, Hyman N (1995) Self-reported functioning and well-being in patients with Parkinson’s disease: comparison of the short-form Health Survey (SF-36) and the Parkinson’s Disease Questionnaire (PDQ-39). Age Ageing 24: 505–509

    Article  PubMed  CAS  Google Scholar 

  15. Hunt SM, McKenna SP, McEwen J (1989) The Nottingham Health Profile: User’s Manual, revised edn. Manchester University

  16. Hunt SM, McKenna SP (1992) Validating the SF-36. BMJ 305: 645

    Article  PubMed  CAS  Google Scholar 

  17. Robinson BC (1983) Validation of a caregiver strain index. J Gerontol 38: 351–353

    Google Scholar 

  18. ALS CNTF Treatment Study (ACTS) Phase I–II Study Group (1996) The amyotrophic lateral sclerosis functional rating scale; assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 53: 141–147

    Google Scholar 

  19. Norris F, Shepherd R, Denys E, et al (1993) Onset, natural history and outcome in idiopathic motor neuron disease. J Neurol Sci 118: 48–55

    Article  PubMed  CAS  Google Scholar 

  20. Haverkamp LJ, Appel V, Appel SH (1995) Natural history of amyotrophic lateral sclerosis in a database population. Brain 118: 707–719

    Article  PubMed  Google Scholar 

  21. Bergner JL, Bobbitt RA, Pollard W, Martin DP, Gilson BS (1976) The Sickness Impact Profile; validation of a health status measure. Med Care 14: 57–67

    Article  PubMed  CAS  Google Scholar 

  22. Polgar J, Thomas V (1991) Introduction to research in health services. Churchill-Livingstone, Edinburgh

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, The Royal London Hospital, E1 1BB, London, UK

    Michael Swash

Authors
  1. Michael Swash
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Swash, M. Health outcome and quality-of-life measurements in amyotrophic lateral sclerosis. J Neurol 244 (Suppl 2), S26–S29 (1997). https://doi.org/10.1007/BF03160578

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03160578

Key words

Search

Navigation